Literature DB >> 1973640

Role of the sympathetic nervous system in the genesis of ventricular arrhythmia.

P J Podrid1, T Fuchs, R Candinas.   

Abstract

Activation of the sympathetic nervous system is an important factor in the genesis of ventricular arrhythmias in patients with impaired ventricular function. Such patients have an appropriate substrate that is capable of generating rhythm abnormalities, which may be related to enhanced automaticity, triggered automaticity, and reentrant mechanisms; all three mechanisms are markedly potentiated by the action of catecholamines. Additionally, the sympathetic nervous system can provoke the development of hypokalemia and ischemia (which can independently lead to the occurrence of rhythm disturbances), and catecholamines may negate the beneficial electrophysiological actions of antiarrhythmic drugs. A substantial amount of experimental data implicates the sympathetic nervous system as a potent stimulus for ventricular tachyarrhythmias and sudden cardiac death, especially in the setting of myocardial ischemia. Two important mechanisms that have been identified include 1) enhanced sympathetic outflow from the central nervous system and 2) nonuniform myocardial denervation resulting in beta-receptor up-regulation and catecholamine hypersensitivity in the infarct zone. Disruption of sympathetic neural innervation of the heart and the use of beta-blocking agents may reduce the occurrence of sudden death and improve survival in animal models of arrhythmias and in some subsets of patients, including those with the long QT syndrome, a recent myocardial infarction, and perhaps those with a cardiomyopathy. The mechanism of this beneficial effect remains to be defined.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1973640

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  60 in total

1.  A shocking case of pseudoephedrine use.

Authors:  D R Goldstein; A E Epstein
Journal:  J Interv Card Electrophysiol       Date:  1999-12       Impact factor: 1.900

2.  Association of anhedonia with recurrent major adverse cardiac events and mortality 1 year after acute coronary syndrome.

Authors:  Karina W Davidson; Matthew M Burg; Ian M Kronish; Daichi Shimbo; Lucia Dettenborn; Roxana Mehran; David Vorchheimer; Lynn Clemow; Joseph E Schwartz; Francois Lespérance; Nina Rieckmann
Journal:  Arch Gen Psychiatry       Date:  2010-05

3.  Prognostic significance of PVCs and resting heart rate.

Authors:  Gregory Engel; Shaun Cho; Afshin Ghayoumi; Takuya Yamazaki; Sung Chun; William F Fearon; Victor F Froelicher
Journal:  Ann Noninvasive Electrocardiol       Date:  2007-04       Impact factor: 1.468

4.  Association of depressive and anxiety symptoms with 24-hour urinary catecholamines in individuals with untreated high blood pressure.

Authors:  Nicola J Paine; Lana L Watkins; James A Blumenthal; Cynthia M Kuhn; Andrew Sherwood
Journal:  Psychosom Med       Date:  2015 Feb-Mar       Impact factor: 4.312

5.  Relationship between impaired cardiac sympathetic activity and spatial dyssynchrony in patients with non-ischemic heart failure: assessment by MIBG scintigraphy and tagged MRI.

Authors:  Masato Yonezawa; Michinobu Nagao; Koichiro Abe; Yoshio Matsuo; Shingo Baba; Takeshi Kamitani; Takuro Isoda; Yasuhiro Maruoka; Mikako Jinnouchi; Yuzo Yamasaki; Kohtaro Abe; Taiki Higo; Takashi Yoshiura; Hiroshi Honda
Journal:  J Nucl Cardiol       Date:  2013-05-08       Impact factor: 5.952

Review 6.  Modulation of the QT interval duration in hypertension with antihypertensive treatment.

Authors:  Jan Klimas; Peter Kruzliak; Simon W Rabkin
Journal:  Hypertens Res       Date:  2015-03-19       Impact factor: 3.872

7.  Depression and CHD risk: how should we intervene?

Authors:  Susmita Parashar; Viola Vaccarino
Journal:  Curr Treat Options Cardiovasc Med       Date:  2007-08

8.  A Retinoic Acid β2-Receptor Agonist Exerts Cardioprotective Effects.

Authors:  Alice Marino; Takuya Sakamoto; Xiao-Han Tang; Lorraine J Gudas; Roberto Levi
Journal:  J Pharmacol Exp Ther       Date:  2018-06-15       Impact factor: 4.030

9.  Plasma catecholamine levels during exposure to an environment of hyperbaric oxygen.

Authors:  K P Tremellen; J A Williamson; D B Frewin; W J Russell
Journal:  Clin Auton Res       Date:  1993-04       Impact factor: 4.435

10.  Clinical impact of vasopressin infusion on hemodynamics, liver and renal function in pediatric patients.

Authors:  Nameet Jerath; Helena Frndova; Brian W McCrindle; Rebecca Gurofsky; Tilman Humpl
Journal:  Intensive Care Med       Date:  2008-03-19       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.